Teva can pursue migraine patent dispute against Eli Lilly

Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Eli Lilly secures trade secret suit dismissal

27 September 2022 Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.

Big Pharma

Eli Lilly avoids sanctions in Teva migraine treatment dispute

13 January 2022 Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.

Big Pharma

Eli Lilly can’t avoid royalties in insulin suit

21 October 2021 Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Teva can pursue migraine patent dispute against Eli Lilly

More on this story

Editor's picks

Editor's picks

More features